IGBA General Statement on WHO's Executive Board Meeting 154 (January 2024)
The International Generic and Biosimilar Medicines Association (IGBA), giving voice to the manufacturers of quality-assured, safe, and cost-effective generic and biosimilar medicines, welcomes the World Health Organization Executive Board’s focus on the Three Billion Targets in the EB154 agenda, linking the learnings from the General Programme of Work 13 (GPW13) to the newly developed GPW14 to accelerate progress in global health.
